公开(公告)号：US20190234917A1

公开(公告)日：2019-08-01

申请号：US16265571

申请日：2019-02-01

申请人： The Cleveland Clinic Foundation

发明人： Stanley L. Hazen ,  Zeneng Wang ,  Bruce L. Levison

IPC分类号： G01N30/88 ,  A61K31/7036 ,  C12Q1/02 ,  A61K31/43 ,  A61K31/4164 ,  A61K31/496 ,  C12Q1/18 ,  G01N33/68

CPC分类号： G01N30/88 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/496 ,  A61K31/7036 ,  C12Q1/025 ,  C12Q1/18 ,  G01N30/7233 ,  G01N33/6893 ,  G01N2030/8813 ,  G01N2030/8822 ,  G01N2800/04 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2030/884

摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.